<DOC>
	<DOCNO>NCT01530399</DOCNO>
	<brief_summary>The objective study determine dose response relationship regard blood loss , PK , PD clinical outcome MDCO-2010 comparison placebo tranexamic acid patient undergoing primary cardiac surgery cardiopulmonary bypass . The aim study define minimally effective dose MDCO-2010 .</brief_summary>
	<brief_title>Phase II Study Compare MDCO-2010 v Placebo Tranexamic Acid Patients Undergoing Cardiac Surgery</brief_title>
	<detailed_description>This two-stage , double-blind , randomize , parallel-group , multicenter Phase II dose-selection study compare antifibrinolytic MDCO-2010 v tranexamic acid placebo reduce blood loss . This study design examine broad range dos fully characterize dose-response relationship MDCO-2010 dose , plasma PK , PD , clinical effect . In Stage 1 , 90 patient enrol one six treatment group 15 patient per group : four group receive MDCO-2010 , one group receive tranexamic acid , one group receive placebo . Stage 2 expansion Stage 1 . The study terminate 49 patient enrol Stage 1 .</detailed_description>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>For Stage 1 : Planned primary isolated CABG surgery For Stage 2 : Planned primary isolated CABG surgery , OR Planned primary combine CABG aortic valve replacement surgery Men , age 18 85 year , Women , age 18 85 year , either postmenopausal status , define ≥1 year since last menstrual period AND le 65 year old negative preoperative pregnancy test within 24 hour surgery OR medical history hysterectomy bilateral oophorectomy Written inform consent Offpump surgery hybrid procedure Patients undergo repeat sternotomy Planned deep hypothermic circulatory arrest ( &lt; 28°C ) Known allergy , sensitivity , contraindication tranexamic acid Epileptiform disorder , history seizure activity , anticonvulsive medication Administration clopidogrel , ticagrelor ticlopidine within 5 day prior surgery prasugrel within 7 day prior surgery . Administration low molecular weight heparin , glycoprotein IIb/IIIa inhibitor , fondaparinux within 12 hour prior surgery Known history coronary stent thrombosis within last three month History stroke transient ischemic attack within 3 month prior surgery History deep venous thrombosis pulmonary embolism LVEF ≤35 % Grade III IV Body mass index &lt; 20 &gt; 35 Known active gastrointestinal ( GI ) noncatheterization bleed within 7 day prior surgery Preoperative coagulation abnormality define : Platelet count &lt; 100,000/L &gt; 350,000/L , International normalize ration ( INR ) &gt; 1.5 , Hematocrit &lt; 36 % , aPTT &gt; 1.5 x ULN Major surgical procedure within 30 day prior surgery Patient inability refusal receive donor blood product necessary Creatinine &gt; 2 mg/dL estimate glomerular filtration rate ( eGFR ) ( calculate use Modification Diet Renal Disease [ MDRD ] equation &lt; 30 mL/min ) Known heparininduced thrombocytopenia type II Known history thrombophilia , ATIII , Protein C Protein S deficiency , Factor V Leiden , antiphospholipid syndrome Active liver disease define know current infectious , neoplastic metabolic pathology liver OR ALT AST elevation &gt; 2x ULN total bilirubin elevation &gt; 1.5x ULN Screening Any condition require ongoing chronic immunosuppressive medication Malignancy within 5 year prior surgery Receipt investigational drug device within 60 day prior surgery Any condition , opinion Principal Investigator , would put subject increase risk participate study otherwise prevent patient‟s participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>